Nora Therapeutics Co-Founder a Perfect Fit to Help Guide Technology Transfer Activities at University of Maryland, Baltimore

BALTIMORE, MD, July 28, 2016 – Today, University of Maryland (UM) Ventures announced the appointment of Darryl L. Carter, MD, co-founder and former vice president of Nora Therapeutics, Inc., as Venture Advisor at the University of Maryland Baltimore’s (UMB) Office of Technology Transfer (OTT). In this role, Dr. Carter, who previously supported UMB’s OTT and entrepreneurially focused inventors as an entrepreneur-in-residence, will assist faculty in turning their technology inventions into commercial opportunities. Dr. Carter will also help support the formation of new UMB technology-based start-up companies.

Dr. Carter co-founded Nora Therapeutics in 2008 as a specialty biopharmaceutical company focused on developing therapies for unmet clinical needs in reproductive health. The firm’s lead drug candidate, NT100, is a therapeutic designed to reduce the risk of miscarriages in women who have a history of recurrent miscarriages. In Dr. Carter’s most recent role as Nora’s vice president of research, he led the company’s biomarker program and drove research efforts for NT100. Dr. Carter was also instrumental in the company’s raising of $25 million in Series A financing, and $28 million in follow-up rounds from five top-tier venture capital firms.

“I welcome the opportunity to expand my involvement at UMB by taking on the venture advisor role,” said Dr. Carter. “There’s a plethora of promising technology coming out of the university as well as startups birthed from university-derived innovations. With the proper guidance and direction, we can drive these efforts towards commercializing new healthcare treatments and medical devices for patients in need.”

Dr. Carter added, “Nora Therapeutics provided me with the opportunity to advance what began as a mere idea all the way through Phase 2 clinical trials. I gained so much experience on that journey, from inventing a novel drug stability assay for NT100 (which the U.S. Food & Drug Administration (FDA) accepted) to creating a clinical advisory board comprised of some of the country’s most highly respected reproductive medicine experts. It’s incredibly gratifying to take an idea from conception to commercialization, and thus I really the opportunity to work with UMB faculty members from the earliest stages of their own ventures.”

Dr. Carter received his medical degree from the University of Medicine and Dentistry of New Jersey, where he held a residency in Anatomic Pathology and Clinical Laboratory Medicine. He then completed post-graduate fellowships at the National Institutes of Health (NIH) and Johns Hopkins University. Dr. Carter previously served as a faculty member of the Johns Hopkins School of Medicine and as an attending physician in diagnostic immunology at Johns Hopkins Hospital. Dr. Carter is the sole inventor on 14 issued patents.

UM Ventures Chief Commercialization Officer Phil Robilotto, D.O., M.B.A., said, “We are extremely pleased to have Dr. Carter expand his role within UMB’s Office of Technology Transfer. He is a researcher and clinician with first-hand experience launching and managing early-stage therapeutic companies, and his expertise in this area will be an incredible asset to both the OTT team and UMB faculty members.”

About UM Ventures

UM Ventures is an initiative to channel the tremendous technical resources and research expertise of the University of Maryland, engaging partners in industry and social ventures to expand real world impact. By encouraging students and faculty, providing expert advice and business services, more discoveries will reach the market. By engaging directly with external partners UM Ventures brings new investment, expanded markets and more start-up ventures. Visit http://umventures.org/ to learn more.

# # #

Media contact:
Juliette Bogus
[email protected]
410-980-5687